Statement on the second meeting of the International Health Regulations Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)

The second meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) regarding the outbreak of novel coronavirus 2019 took place on Thursday, 30 January 2020. China quickly identified the virus and shared its sequence, so that other countries are now able to  diagnose it quickly and protect […]

Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose

Hepatitis B remains a global major public health issue and a viral infection transmissible by transfusion. The risk of HBV transfusion transmitted infection has been reduced by the selection of donors; the continuous improvement of serological assays to detect the HBV surface antigen (HBsAg); the implementation of anti-HBc screening for antibodies against the HBV core […]

Epidemiological characteristics of human prion diseases

In the absence of specific therapies for human prion diseases, which are frequently associated with neurodegenerative disorders with fatal outcome, only an active surveillance can be used to monitor and prevent the transmission of such diseases. For this reason, starting from 1993, surveillance systems have been established in many countries. Moreover, there is urgent need […]

Current state of play regarding dental extractions in patients with haemophilia: Consensus or evidence‐based practice? A review of the literature

Tooth extractions are quite common surgical procedures in patients with haemophilia, in particular in older age or in countries with restricted resources.  Uptodate, the optimal management of replacement therapy (RT, dosage and duration of treatment) are scant and only low levels of evidence are available.  A recent article has reviewed the haematological treatment protocols and […]

DAMOCTOCOG ALFA PEGOL: A REVIEW IN HAEMOPHILIA A

Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for the treatment and prophylaxis of previously treated patients aged ≥ 12 years with haemophilia A. Formulated with a 60 kDa polyethylene glycol (PEG) moiety, damoctocog alfa pegol is an intravenously (IV) administered recombinant factor VIII (rFVIII) product with a longer terminal half-life than non-PEGylated FVIII […]